Journal of Clinical Oncology

One-year access to more than 500 world journals available in the system

Duration of Time : 365 Day
~~Price : 300$~~
Special Price : 100$

Order

Primary Tumor Resection in Colorectal Cancer With Synchronous Unresectable Metastasis: Time to End the Debate?

George J. Chang , MD, MS1

doi : 10.1200/JCO.21.00057

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1095-1097.

Buy The Package and View The Article Online

Primary Tumor Resection Plus Chemotherapy Versus Chemotherapy Alone for Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastases (JCOG1007; iPACS): A Randomized Clinical Trial

Yukihide Kanemitsu , MD1; Kohei Shitara , MD2; Junki Mizusawa, ME1; Tetsuya Hamaguchi, MD, PhD3; Dai Shida , MD, PhD1; Koji Komori , MD, PhD4; Satoshi Ikeda, MD, PhD5; Hitoshi Ojima, MD, PhD6; Hideyuki Ike, MD, PhD7; Akio Shiomi, MD8; Jun Watanabe , MD, PhD9; Yasumasa Takii , MD10; Takashi Yamaguchi, MD11; Kenji Katsumata, MD, PhD12; Masaaki Ito , MD, PhD2; Junji Okuda, MD, PhD13; Ryoji Hyakudomi, MD14; Yasuhiro Shimada, MD15; Hiroshi Katayama, MD1; Haruhiko Fukuda, MD1; and JCOG Colorectal Cancer Study Group

doi : 10.1200/JCO.20.02447

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1098-1107.

It remains controversial whether primary tumor resection (PTR) before chemotherapy improves survival in patients with colorectal cancer (CRC) with asymptomatic primary tumor and synchronous unresectable metastases.

Buy The Package and View The Article Online

Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)

J. Randolph Hecht , MD1; Sara Lonardi , MD2; Johanna Bendell, MD3; Hao-Wen Sim , MBBS, FRACP4,5; Teresa Macarulla, MD6; Charles D. Lopez, MD, PhD7; Eric Van Cutsem , MD, PhD8; Andres J. Mu?oz Martin , MD, PhD9; Joon Oh Park , MD, PhD10; Richard Greil , MD11; Hong Wang, PhD12; Rebecca R. Hozak, PhD12; Ivelina Gueorguieva, PhD12; Yong Lin, PhD13; Sujata Rao, MD12; and Baek-Yeol Ryoo , MD14

doi : 10.1200/JCO.20.02232

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1108-1118.

SEQUOIA compared efficacy and safety of adding pegilodecakin (PEG), a pegylated recombinant human interleukin (IL)-10, with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) in patients following progression on first-line gemcitabine-containing therapy with metastatic pancreatic ductal adenocarcinoma (PDAC).

Buy The Package and View The Article Online

Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma

Kishan K. Patel, BS1; Smith Giri, MD, MHS2; Terri L. Parker, MD1; Noffar Bar, MD1; Natalia Neparidze, MD1; and Scott F. Huntington, MD, MPH, MSc1,3

doi : 10.1200/JCO.20.01849

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1119-1128.

The MAIA trial found that addition of daratumumab to lenalidomide and dexamethasone (DRd) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma, compared with lenalidomide and dexamethasone alone (Rd). However, daratumumab is a costly treatment and is administered indefinitely until disease progression. Therefore, it is unclear whether it is cost-effective to use daratumumab in the first-line setting compared with reserving its use until later lines of therapy.

Buy The Package and View The Article Online

Burkitt Lymphoma International Prognostic Index

Adam J. Olszewski, MD1; Lasse H. Jakobsen, PhD2; Graham P. Collins, MD, DPhil3; Kate Cwynarski, MBBS, PhD4; Veronika Bachanova, MD5; Kristie A. Blum, MD6; Kirsten M. Boughan, DO7; Mark Bower, MD8; Alessia Dalla Pria, MD8; Alexey Danilov, MD, PhD9; Kevin A. David, MD10; Catherine Diefenbach, MD11; Fredrik Ellin, MD, PhD12; Narendranath Epperla, MD, MS13; Umar Farooq, MD14; Tatyana A. Feldman, MD15; Alina S. Gerrie, MD, MPH16; Deepa Jagadeesh, MD17; Manali Kamdar, MD, MBBS18; Reem Karmali, MD, MSc19; Shireen Kassam, MBBS, PhD20; Vaishalee P. Kenkre, MD21; Nadia Khan, MD22; Seo-Hyun Kim, MD23; Andreas K. Klein, MD24; Izidore S. Lossos, MD25; Matthew A. Lunning, DO26; Peter Martin, MD, MS27; Nicolas Martinez-Calle, MD, PhD28; Silvia Montoto, MD29; Seema Naik, MD30; Neil Palmisiano, MD, MS31; David Peace, MD32; Elizabeth H. Phillips, MBBS, BSc33; Tycel J. Phillips, MD34; Craig A. Portell, MD35; Nishitha Reddy, MD, MBBS36; Anna Santarsieri, MBBS37; Maryam Sarraf Yazdy, MD38; Knut B. Smeland, MD39; Scott E. Smith, MD, PhD40; Stephen D. Smith, MD41; Suchitra Sundaram, MD42; Adam S. Zayac, MD1; Xiao-Yin Zhang, PhD3; Catherine Zhu, MD4; Chan Y. Cheah, MBBS43; Tarec C. El-Galaly, MD44; Andrew M. Evens, DO, MSc10 on behalf of The Burkitt Lymphoma International Prognostic Index consortium

doi : 10.1200/JCO.20.03288

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1129-1138.

Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches.

Buy The Package and View The Article Online

Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR

Hervé Avet-Loiseau , MD1; Jesus San-Miguel , MD2; Tineke Casneuf, PhD3; Shinsuke Iida , MD4; Sagar Lonial , MD5; Saad Z. Usmani , MD6; Andrew Spencer, MD7; Philippe Moreau, MD8; Torben Plesner, MD9; Katja Weisel, MD10; Jon Ukropec, PhD11; Christopher Chiu, PhD12; Sonali Trivedi, PhD12; Himal Amin, BS13; Maria Krevvata, PhD12; Priya Ramaswami, MSPH14; Xiang Qin, MS12; Mia Qi, PhD13; Steven Sun, PhD13; Ming Qi, MD12; Rachel Kobos, MD13; and Nizar J. Bahlis , MD15

doi : 10.1200/JCO.20.01814

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1139-1149.

In relapsed and/or refractory multiple myeloma, daratumumab reduced the risk of progression or death by > 60% in POLLUX (daratumumab/lenalidomide/dexamethasone [D-Rd]) and CASTOR (daratumumab/bortezomib/dexamethasone [D-Vd]). Minimal residual disease (MRD) is a sensitive measure of disease control. Sustained MRD negativity and outcomes were evaluated in these studies.

Buy The Package and View The Article Online

CanDirect: Effectiveness of a Telephone-Supported Depression Self-Care Intervention for Cancer Survivors

Jane McCusker, MD, DrPH1; Jennifer M. Jones, PhD2; Madeline Li, MD, PhD2; Rosana Faria, MPs3; Mark J. Yaffe, BSc, MDCM, MClSc3; Sylvie D. Lambert, PhD4; Antonio Ciampi, PhD1; Eric Belzile, MSc1; and Manon de Raad, BComm1

doi : 10.1200/JCO.20.01802

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1150-1161.

Depression in post-treatment cancer survivors is common and can impair quality of life. CanDirect is a novel, telephone-delivered depression self-care intervention for cancer survivors. We conducted a randomized controlled superiority trial to compare CanDirect with usual care (UC) in this population.

Buy The Package and View The Article Online

This Is Not Happening

Sarah J. Ramer , MD, MS1

doi : 10.1200/JCO.20.03298

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1162-1164.

Buy The Package and View The Article Online

Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer

Sonali M. Smith, MD1; Kerri Wachter , BS2; Howard A. Burris III, MD3; Richard L. Schilsky , MD2; Daniel J. George , MD4; Douglas E. Peterson , DMD, PhD5; Melissa L. Johnson, MD3; Merry Jennifer Markham, MD, FACP, FASCO6; Kathryn F. Mileham, MD7; Muhammad S. Beg , MD8; Johanna C. Bendell, MD3; Robert Dreicer, MD, MS, MACP9; Vicki L. Keedy , MD10; Randall J. Kimple , MD, PhD11; Miriam A. Knoll, MD12; Noelle LoConte , MD11; Helen MacKay, MD, MS, MACP13; Jane Lowe Meisel, MD14; Timothy J. Moynihan, MD15; Daniel A. Mulrooney , MD16; Therese Marie Mulvey , MD17; Olatoyosi Odenike, MD1; Nathan A. Pennell , MD, PhD18; Katherine Reeder-Hayes , MD, MBA, MS19; Cardinale Smith , MD, PhD20; Ryan J. Sullivan , MD17; and Robert Uzzo, MD, MBA21

doi : 10.1200/JCO.20.03420

Journal of Clinical Oncology 39, no. 10 (April 01, 2021) 1165-1184.

Buy The Package and View The Article Online